复发/难治性B细胞急性淋巴细胞白血病（R/R B-ALL）是成人患者中的一种具有低复发率和生存率的问题性疾病。抗CD19嵌合抗原受体T细胞（CAR-T细胞）疗法已被批准用于这些患者。最近，双靶点抗CD19和CD22的CAR-T细胞已被开发用于提高单靶点疗法的疗效; 然而，尚需确定这种双靶点疗法的改善程度。我们对CAR-T细胞疗法的结果和安全性进行了荟萃分析，比较了抗CD19 vs 抗CD22 vs 双靶点抗CD19/CD22 CAR-T细胞在成年R/R B-ALL患者中的差异和限制。尽管我们的研究存在于包括的出版物中的异质性，但我们的结果表明与单靶点抗CD19和抗CD22 CAR-T细胞相比，抗CD19/CD22 CAR-T细胞引起的复发和神经毒性发生率较低，但在完全缓解，微小残留病，总生存和细胞因子释放综合征方面获得了类似的结果。

Relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a challenging disease with low rates of remission and survival in adult patients. Anti-CD19 Chimeric Antigen Receptor T-cells (CAR-Ts) therapies have been approved for these patients. Dual-target CAR-Ts against CD19 and CD22 have recently been developed to improve the efficacy of the single-target therapy; however, extent of the improvement using this dual-target therapy has yet to be determined. We performed a meta-analysis of the outcome and safety of CAR-Ts, comparing anti-CD19 vs anti-CD22 vs dual-target anti-CD19/CD22 CAR-Ts, to elucidate the differences and limitations of these therapies in adult patients with R/R B-ALL. Although the limitations of our study derived from heterogeneity in the included publications, our results suggest that anti-CD19/CD22 CAR-Ts generate lower incidence of relapse and neurotoxicity, but similar results were obtained regarding complete remission, minimal residual disease, overall survival, and cytokine release syndrome compared with single-target anti-CD19 and anti-CD22 CAR-Ts.